^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Real-world outcomes in patients with KRAS G12C–mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond

Published date:
05/25/2023
Excerpt:
...we provide real-world clinicopathological characteristics, treatment patterns, and survival outcomes data in patients with KRAS mutation–positive advanced NSCLC (aNSCLC), including those with KRAS G12C and KRAS non-G12C mutations, who received docetaxel as standard-of-care treatment in the second-line and beyond (2L+)....Real-world outcomes were poor in patients with KRAS G12C–mutated aNSCLC treated with 2L+ docetaxel.
DOI:
https://doi.org/10.1016/j.lungcan.2023.107260
Evidence Level:
Resistant: C3 – Early Trials
Title:

A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer

Published date:
02/08/2023
Excerpt:
...median rwPFS 4.6 months (95% CI, 1.4-NA) among 10 docetaxel-treated patients (9 received docetaxel and 1 received docetaxel plus ramucirumab)....we observed a relatively short median rwPFS of 4.6 months among 10 patients with KRAS G12C mutant NSCLC treated with docetaxel with or without ramucirumab in the second-line setting...
DOI:
10.1016/j.cllc.2023.01.009
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Real-world outcomes in patients with KRAS p.G12C mutant advanced non-small cell lung cancer (aNSCLC) treated with docetaxel in second-line or beyond (2L+).

Published date:
05/26/2022
Excerpt:
Analyses were performed for cohorts of patients with KRAS p.G12C mutation and KRAS non-p.G12C mutation, separately....Real-world outcomes are poor in patients with KRAS p.G12C mutant aNSCLC treated with docetaxel in 2L or beyond, with a median OS of only 6 months.
DOI:
10.1200/JCO.2022.40.16_suppl.e21048